-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LSqbQpl2oX+kmTWnxj/U7GgCS5E6TG+u14PLhS8e7t28HwGhgaSETb8NNOR+4R3R
 YetDOJPHioMn+h5WyRVoZw==

<SEC-DOCUMENT>0001077048-04-000498.txt : 20041230
<SEC-HEADER>0001077048-04-000498.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230172239
ACCESSION NUMBER:		0001077048-04-000498
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041230
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHEMOKINE THERAPEUTICS CORP
		CENTRAL INDEX KEY:			0001092959
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51080
		FILM NUMBER:		041234930

	BUSINESS ADDRESS:	
		STREET 1:		4400 MACARTHUR BLVD
		STREET 2:		SUITE 500
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTM MOLECULAR BIOSYSTEMS INC
		DATE OF NAME CHANGE:	20000204
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>chemokine-8k_123004.htm
<TEXT>
<html>
<body>

<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">UNITED STATES</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">SECURITIES AND
EXCHANGE COMMISSION</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Washington, D.C. 20549</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">______________</p>
<b>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">FORM 8-K</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">CURRENT REPORT</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Pursuant to Section 13
or 15(d) of the</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Securities Exchange
Act of 1934</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</b>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Date of Report (Date
of earliest event reported) <b>December 30, 2004</b></p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0"><b></p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">CHEMOKINE THERAPEUTICS
CORP.</p>
</b>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">(Exact name of
registrant as specified in charter)</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table CELLSPACING="1" WIDTH="100%" border="0">
	<tr>
		<td WIDTH="33%" VALIGN="TOP"><b>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Delaware</b></td>
		<td WIDTH="33%" VALIGN="TOP"><b>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">333-117858</b></td>
		<td WIDTH="33%" VALIGN="TOP"><b>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">33-0921251</b></td>
	</tr>
	<tr>
		<td WIDTH="33%" VALIGN="TOP">
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">(State or
		other jurisdiction<br>
		of incorporation)</td>
		<td WIDTH="33%" VALIGN="TOP">
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">(Commission<br>
		File Number)</td>
		<td WIDTH="33%" VALIGN="TOP">
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">(IRS Employer<br>
		Identification No.)</td>
	</tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table CELLSPACING="1" WIDTH="100%" id="table1" border="0">
	<tr>
		<td WIDTH="75%" VALIGN="TOP"><b>
		<p style="margin-top: 0; margin-bottom: 0">2386 East Mall Street, Suite
		208<br>
		University of British Columbia</p>
		<p style="margin-top: 0; margin-bottom: 0">Vancouver, British Columbia
		</b></td>
		<td WIDTH="25%" VALIGN="TOP"><b>
		</b>
		<p ALIGN="RIGHT" style="margin-top: 0; margin-bottom: 0">&nbsp;<p ALIGN="RIGHT" style="margin-top: 0; margin-bottom: 0">&nbsp;<p ALIGN="RIGHT" style="margin-top: 0; margin-bottom: 0">
		<b>V6T 1Z3</b></td>
	</tr>
	<tr>
		<td WIDTH="75%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">(Address of principal
		executive offices)</td>
		<td WIDTH="25%" VALIGN="TOP">
		<p ALIGN="RIGHT" style="margin-top: 0; margin-bottom: 0">(Zip Code)</td>
	</tr>
</table>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Registrant's telephone
number, including area code <u><b>(604) 822-0301</b></u></p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">(Former Name or Former
Address, if Changed Since Last Report.)</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions (see General Instruction
A.2. below): </p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) </p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) </p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)) </p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)) </p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<hr>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">ITEM 8.01. <u>Other Events.</p>
</u>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">On December 30, 2004,
Chemokine Therapeutics Corp. (the &quot;Registrant&quot;) issued a press release
announcing its initial public offering consisting of 16,000,000 shares of its
common stock. Attached as Exhibit 99.1 are copies of the Registrant's December
30, 2004 press release. </p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">ITEM 9.01. <u>
Financial Statements and Exhibits.</p>
</u>
<ol type="a">
	<li>
	<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Not applicable.</li>
	<li>
	<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Not applicable.</li>
	<li>
	<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Exhibits.</li>
</ol>
<table CELLSPACING="1" BORDER="0" WIDTH="100%">
	<tr>
		<td WIDTH="12%" VALIGN="TOP"><b>
		<p style="margin-top: 0; margin-bottom: 0">Exhibit Number</b></td>
		<td WIDTH="86%" VALIGN="TOP"><b>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0"></p>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Description of
		Exhibit</b></td>
	</tr>
	<tr>
		<td WIDTH="12%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">99.1</td>
		<td WIDTH="86%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">Press Release of Registrant,
		dated December 30, 2004, announcing the Registrant's initial public
		offering.</td>
	</tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<hr>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">SIGNATURE</p>
<p style="margin-top: 0; margin-bottom: 0">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Company has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table CELLSPACING="1" BORDER="0" WIDTH="100%">
	<tr>
		<td WIDTH="50%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0"><br>
		<br>
		<br>
		<br>
		Date: December 30, 2004</td>
		<td WIDTH="50%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">Chemokine Therapeutics Corp.,</p>
		<p style="margin-top: 0; margin-bottom: 0">a Delaware corporation<br>
		<br>
		<br>
		<br>
		By:<u> /s/ Hassan Salari&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</p>
		</u>
		<p style="margin-top: 0; margin-bottom: 0">Hassan Salari<br>
		Chief Executive Officer</td>
	</tr>
</table>
<b>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<hr>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">EXHIBIT INDEX</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</b>
<table CELLSPACING="1" BORDER="0" WIDTH="100%">
	<tr>
		<td WIDTH="12%" VALIGN="TOP"><b>
		<p style="margin-top: 0; margin-bottom: 0">Exhibit Number</b></td>
		<td WIDTH="86%" VALIGN="TOP"><b>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0"></p>
		<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">Description of
		Exhibit</b></td>
	</tr>
	<tr>
		<td WIDTH="12%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">99.1</td>
		<td WIDTH="86%" VALIGN="TOP">
		<p style="margin-top: 0; margin-bottom: 0">Press Release of Registrant,
		dated December 30, 2004, announcing the Registrant's initial public
		offering.</td>
	</tr>
</table>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0"></p>

</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 30, 2004
<TEXT>
<html>
<body>

<font FACE="Arial"><b>
<p style="margin-top: 0; margin-bottom: 0" align="right">
<img border="0" src="logo.gif" width="52" height="70">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
<p style="margin-top: 0; margin-bottom: 0" align="right">Chemokine Therapeutics</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table border="0" width="100%" id="table1" cellspacing="1">
	<tr>
		<td>
		<p style="margin-top: 0; margin-bottom: 0"><font FACE="Arial"><b>FOR
		IMMEDIATE RELEASE&nbsp;&nbsp; </b></font></td>
		<td>
		<p style="margin-top: 0; margin-bottom: 0" align="right">
		<font FACE="Arial"><b>TSX symbol: CTI</b></font></td>
	</tr>
</table>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">CHEMOKINE COMPLETES
INITIAL PUBLIC OFFERING</p>
</b><i>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">- Shares listed on TSX
under the symbol &quot;CTI&quot; -</p>
</i></font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">VANCOUVER, British
Columbia - December 30, 2004 -</b> Chemokine Therapeutics Corp. (TSX:CTI), a
biotechnology company developing drugs in the field of chemokines and cytokines,
today announced its initial public offering, consisting of a new issue of
16,000,000 common shares priced at Cdn$1.00 per share, for gross proceeds of
Cdn$16,000,000. Chemokine Therapeutics' common shares are expected to trade on
the Toronto Stock Exchange under the symbol &quot;CTI&quot; at market opening today.</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">A syndicate of
investment dealers led by Canaccord Capital Corporation and including Jennings
Capital Inc., McFarlane Gordon Inc., and Wellington West Capital Inc.,
participated in the financing. Chemokine has granted the underwriters an option,
exercisable for a period of 60 days from the closing date, to purchase an
additional 2,400,000 common shares to cover over allotments, and for market
stabilization purposes. If the over-allotment is exercised in full, total
maximum gross proceeds of the offering will be approximately Cdn$18,400,000.</font>
</p>
<font SIZE="2"><i>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of the common shares in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state. Copies of the final prospectus relating
to the offering may be obtained from Chemokine Therapeutics Corp. located at
208-2386 East Mall (UBC), Vancouver, B.C., V6T 1Z3.</p>
</i></font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">About Chemokine
Therapeutics Corp. (www.chemokine.net)</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Chemokine
Therapeutics Corp. is a biotechnology company focused on chemokines, a family of
small, soluble proteins, structurally related to cytokines. Chemokines play a
role in controlling normal body functions such as immune response and stem cell
development and in the physiological processes of a variety of diseases
including cancer, viral infections, and autoimmune diseases. Chemokine
Therapeutics is developing synthetic chemokines to address a number of diseases
and disorders. Its two drug candidates in clinical trials are CTCE-0214, a
hematological support compound, and CTCE-9908, an anti-metastasis compound. In
addition, Chemokine Therapeutics maintains a drug discovery program to identify
new chemokine-based drug candidates. Pharmaceutical Product Development, Inc. (PPDI)
and Proctor &amp; Gamble Pharmaceuticals, Inc. have signed strategic agreements with
Chemokine Therapeutics to collaborate on research and development.</p>
</font><i><font SIZE="2">
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Statements in this
press release regarding the expected use of the proceeds from the offering of
Chemokine common shares and any other statements, managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual results
to differ materially from the statements made. For this purpose, any statements
that are contained herein that are not statements of historical fact may be
deemed to be forward-looking statements made pursuant to the safe harbor
provisions of the United States Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, the words &quot;believes&quot;, &quot;anticipates&quot;,
&quot;plans&quot;, &quot;intends&quot;, &quot;will&quot;, &quot;should&quot;, &quot;expects&quot;, &quot;projects&quot;, and similar
expressions are intended to identify forward-looking statements. You are
cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking statements.
These risks include, but are not limited to, those associated with the success
of research and development programs, the regulatory approval process,
competition, securing and maintaining corporate alliances, market acceptance of
the Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any financing,
reliance on subcontractors and key personnel and other risks detailed from
time-to-time in the Company's public disclosure documents or other filings with
the Canadian and U.S. securities commissions or other securities regulatory
bodies. The forward-looking statements are made as of the date hereof, and the
Company disclaims any intention and has no obligation or responsibility, except
as required by law, to update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.</p>
</font></i><font FACE="Arial" SIZE="3"></font><font FACE="Arial" SIZE="2">
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">For further information contact:</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</font>
<table CELLSPACING="1" WIDTH="100%" border="0">
	<tr>
		<td WIDTH="54%" VALIGN="TOP"><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Chemokine
		Therapeutics Corp.</p>
		<p style="margin-top: 0; margin-bottom: 0">Hassan Salari, President and
		CEO, or</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">David Karp,
		Chief Financial Officer</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Phone: (604)
		822-0301</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Fax: (604)
		822-0302</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">E-mail:
		</font><font FACE="Arial">dkarp@chemokine.net</p>
		</font><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Internet:
		</font><font FACE="Arial">www.chemokine.net</font></td>
		<td WIDTH="46%" VALIGN="TOP"><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Investor
		Relations</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Ross Marshall</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">The Equicom
		Group Inc.</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Phone: (416)
		815-0700 (Ext.238)</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">E-mail:
		</font><font FACE="Arial">rmarshall@equicomgroup.com</p>
		</font><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Fax: (416)
		815-0080</font></td>
	</tr>
</table>

</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.gif
<DESCRIPTION>LOGO
<TEXT>
begin 644 logo.gif
M1TE&.#=A-`!&`/<``/______]__W]_?___?W]_>]O?>UM?>MK>_W]^_O[^_G
MY^_>WN?O[^?GY^?6UN=C8^=:6M[GY][>WM[&QMZUM=ZMK=Y24M;6UM;.SM:]
MO=:UM=:EI=8Y.<[.SLZ]O<Z$A,XQ,<XI*<;&QL:MK<:EI<:<G,:4E,:,C,8A
M(;V]O;US<[T8&+6UM;6$A+5K:[40$+4("*VMK:U24J6EI:64E*5K:Z4A(:4(
M"*4``)R<G)Q[>YQ:6IPQ,9P``)24E)0Y.90I*90``(R,C(PI*8PA(8P``(>L
MSH2,C(2$A(08&(00$(0("(0``'ZAP7M[>WLI*7L("'L``':6M'-S<W,0$',(
M"',``&V,IVN.H&MK:VL("&L``&>,H&>+GF:'DF6!FV5\B6-E-V-C8V,``%UV
MCEIZC%I:6EH``%1L@5-R@E)I=E)24DQA=$I*2DE984=A;D17:$)"0D!79#Q-
M7#DY.3D``#@2%#1"3S(S,S$0$"HV02DX0"DI*2<U/",M-2$A(2`L,ALB*1HD
M*1@A)A@8&!,9'1(8'!`0$`T2%`L/$@H-#P@*#`<)"P8("0(#`P$"`@$!`0`!
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````-`!&```(_@`E"1Q(L*#!@P@3*EQ8D(]#
M@G_XX.'SAZ'%A7_PM%ECIDT</`/YQ%DC1LR:.'PNJOQ#IXT9,5.FF'39!D]$
MCANS.'$B\V1*E0?QF'&2(X<0)R;7$(WA@Z<3'S%R3-DXU,<,HUGB5`0J<DJ.
M%"Q\9!D[94:*"V@[B$@AHL,%"1=$2"V9Y:N(&$YJ6A0J9,8,'V;^.'*DZ!"A
M/W\(*5:<>/'AQ(<&._HC)@<+%CFRT%'8QC)4)VO:B`XMNK3ITZA)NX2:0\0,
M,3\+QKEJQD=<L"ERZV:A>W=OW+[!LFCK0\QE,P>G",$SHX.0CAZCQQ$]O3KU
MZ->G8]^(1"Z=&,L;_B)I,^6"$#J'%*E?KX@P^_;OW:N73_@0GRD=LHB9`1(B
M$B=M3<%'>Y(5:."!"!Y(B!DBB"!$#IM!M),0$J0P11SI):CAAHX<0D<6,73P
M5`[]$>1$%H>(<19>6G'HXF`>9C'#76TH(H0/L0VTGV"$K-%<"L7A0>"+!2K"
MQQI"Y"9$'.WAP8(36Q%$AU^"#1:'#QUTD(,8>!`IV1]K^+"6$WQ(QL<,+"!W
MD!G#95$@'D*H)40;?QQ2YYUVYGDG'D[D-D65@V71H(`(@9G#!2S$4>"4B`HA
M!!*/1@KII([.*`2@CK3!P@6OY1@4B.8->0@2+,1@ZJFHQC##J2R(4>`A_T)<
MD((3<:@4!Q(=I-`EAT,.::"3%_BP1I07\:&B"&4.-L5_3B"!A`]'('&$#\SN
MY`2!?*@U18E`"61&"CD$VL`%#0``@`(EN""#"A40```!<2G@IB,A9N%IMWR(
MF6FN(B0@0`M56!%%$$'T8,,&`TA0E`AQ$-)!#+5V6Y`9(>('5@,#['#&%D7T
M\,(**\#0PP<#B(!$#B*JE06Q7&7!VQILB0E`"QL/_$((%E@``@Q!4(#`#"#.
M8+$3W*J$7PYUEII#!`M0,<863-RP@@4''``!"CWP$$`'RL60:0H=(%$T0VW@
MU21<%P!@PAA/1SVU`04\@`(.3$PP0&X2"/9':_YB=#N%#Y+!S)L(.FCQM,T@
M0``!!R_TD`0-(ERFZV!\L'`I4#LEB(@=3UM1Q`TOH(#""S<4D0<C">;@`\L+
MR3B8D11%I$@=6QS^^0VX%Q%%'85$%-&`':9PN4IM6.B(#Q6RT$$")%AA1>U;
M"!S%],]K@4$#*<3`@@1(.`)@WT#]@1^;"<Q`5+D_/%_[TUNT/\89-0`@8A8^
M*/!:L&,S1`>62,2%Q!0Q&,`$H."\];&-;4](0`.>,P6VX"H&;9"80#1%JTV5
M*FT:4$+TU%>[(3@``3%`PHQRP(?N@$^"XA-!%@BAH@MTH%P*4`$1EL`$*`#A
M!`08``;8`K%#X"<\$OX4"!X>J!4DP$4"#$B`!#PP@@PT``'CRA(2"!&'&`0K
M8D$4"!]`E0.4..8P@V@,8S)BFUE%*(L$B8,3E">@-:C&-*'9HEK&PSHT2N(/
MM^)4#-XE@;6(X`+NLHP$9F"&>]F1(,R9P1]\@+TID&0&$I@"(<"RAD,RA%J.
M((0/TH1'H75H56>T9%!B8`;"S&9;9A`;8;JC)E$>9`TL$(R1=A*'+`C(2F%S
M)4*:11A&#-$'RR):>PBA*D.*\@]S@E$5XZ(E.A!H"BP(I2[ON)S!$`(/8G`6
M4H#G"%AB<9K45)1D#D%.0O@*9M\$IQ"F8*8X-4B5@R%5_EP)(OCL+RS@$=%2
M\%8'3H(4KPV4RP$2XO"W9)DA/_TDR)F$L,H4B`&/>!G,5R*84"'&0`1_P%5X
M[A.V/ZBEE?VD0YSZ<L6!\$E+D)Q!)<')!S-8I@UTD$LZX:0K%<4@"_.46$;:
M4!=AL2E-!YE-FEPJM)K4425'*@E,T`2NAR(D3&`QWQ3,T!%C6H0.'2')LYQ@
M!FD:1"-9>)08/&*&=`*%#J%Q(TR/BA"-4.<D6>0#=:S*D(Q,)Z<6\=TA*5+1
>OOKUKWC]ZT#"(%B&T+6P`CDA8A?+V,8ZUJ\!`0`[
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
